Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BTK covalent inhibitor neoantigen program
- Development stage
- Preclinical
- Lead developer
- Aethon Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Aethon Therapeutics is developing a preclinical bispecific T cell engager (BiTE) using its proprietary HapImmune™ platform to target BTK-driven cancers, primarily hematologic malignancies. The therapy targets synthetic neoantigens (haptens) formed when covalent BTK inhibitors bind to their target protein within cancer cells. These drug-peptide conjugates are subsequently processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules. The bispecific antibody is designed to recognize these specific peptide-MHC complexes and simultaneously engage CD3 on T cells, thereby recruiting the immune system to eliminate tumor cells, including those that have developed resistance to standard BTK inhibitor therapy. The program is backed by Apple Tree Partners and utilizes technology licensed from NYU Langone Health.
- Other names
- BTK peptide-MHC neoantigen T cell engagerHapImmune BTK program
02
Targets
BTK-drug-pMHC (Bruton's tyrosine kinase drug-modified peptide–major histocompatibility complex class I complex)CD3 (T-cell surface glycoprotein CD3)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on BTK covalent inhibitor neoantigen program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BTK covalent inhibitor neoantigen program.